TABLE 2.
Efficacy outcomes and safety outcomes
| Characteristics | All patients | χ 2/z value | Unadjusted outcome variable value (95% CI) | p value | Adjusted value (95% CI) | p value | Propensity score matching | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No/Total No. (%) | No/Total No. (%) | χ 2/z value | p value | ||||||||||
| All (n = 1820) | NBP (n = 682) | Non‐NBP (n = 1138) | All (n = 1198) | NBP (n = 599) | Non‐NBP (n = 599) | ||||||||
| Primary efficacy outcomes | |||||||||||||
| Modified Rankin Scale score at 90d, median (IQR) | 4 (2–6) | 3 (2–5) | 4 (2–6) | −5.976 | 1.659 (1.403–1.961) | <0.001 | 1.503 (1.254–1.801) | <0.001 | 3 (1–6) | 3 (1–5) | 4 (2–6) | −4.122 | <0.001 |
| Secondary efficacy outcomes | |||||||||||||
| Modified Rankin Scale score at 90d, No. (%) | |||||||||||||
| 0–3, No. (%) | 864/1820 (47.5) | 378/682 (55.4) | 486/1138 (42.7) | 27.664 | 1.668 (1.378–2.020) | <0.001 | 1.589 (1.251–2.020) | <0.001 | 600/1198 (50.1) | 332/599 (55.4) | 268/599 (44.7) | 13.675 | <0.001 |
| 0–2, No. (%) | 668/1820 (36.7) | 287/682 (42.1) | 381/1138 (33.5) | 13.583 | 1.444 (1.187–1.756) | <0.001 | 1.307 (1.031–1.658) | 0.027 | 455/1198 (38.0) | 253/599 (42.2) | 202/599 (33.7) | 9.217 | 0.003 |
| 0–1, No. (%) | 437/1820 (24.0) | 193/682 (28.3) | 244/1138 (21.4) | 10.992 | 1.446 (1.162–1.799) | 0.001 | 1.362 (1.052–1.763) | 0.019 | 300/1198 (25.0) | 168/599 (28.0) | 132/599 (22.0) | 5.763 | 0.016 |
| Safety outcome | |||||||||||||
| Symptomatic intracranial hemorrhage, No. (%) | 229/1808 (12.7) | 74/682 (10.9) | 155/1126 (13.8) | 3.263 | 0.762 (0.568–1.024) | 0.071 | 0.787 (0.567–1.092) | 0.152 | 132/1198 (11.0) | 62/599 (10.4) | 70/599 (11.7) | 0.545 | 0.460 |
| Mortality at 90 days, No. (%) a | 566/1820 (31.3) | 148/682 (21.7) | 418/1138 (36.7) | 44.959 | 0.477 (0.384–0.594) | <0.001 | 0.486 (0.372–0.635) | <0.001 | 333/1198 (27.8) | 130/599 (21.7) | 203/599 (33.9) | 22.164 | <0.001 |
Abbreviations: CI, confidence interval; IQR, interquartile range.
a
All cause death.